Anthem Biosciences Limited (NSE:ANTHEM)

Market Cap	432.97B
Revenue (ttm)	20.52B
Net Income (ttm)	5.05B
Shares Out	561.61M
EPS (ttm)	8.99
PE Ratio	85.77
Forward PE	69.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,347
Average Volume	470,194
Open	765.00
Previous Close	761.50
Day's Range	752.85 - 774.35
52-Week Range	701.90 - 873.50
Beta	n/a
RSI	38.85
Earnings Date	Nov 13, 2025

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,825
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ANTHEM

Financial Performance

In 2024, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.